AstraZeneca, BMS weigh mega-merger

Media reports citing the Financial Times said AstraZeneca and U.S.-based Bristol Myers Squibb (BMY) have held early-stage discussions about a potential merger. The proposed tie-up would bring together two major oncology and pharmaceutical players into a group that reports said could be valued at roughly $400 billion. Such a transaction would create one of the world’s largest drugmakers by market value.

The reports described the talks as preliminary, with few concrete details on structure or terms. Neither side has announced any formal proposal or agreement, and there has been no indication that negotiations are advanced. The lack of confirmation left investors and analysts to assess the implications based largely on the scale of the potential combination.

News of the talks triggered an immediate market reaction in London. AstraZeneca’s FTSE 100 (UKX)-listed shares fell 8.9% to close at £115, according to one account of the session. The drop wiped more than £17 billion off the company’s market value and reduced its overall capitalisation to about £178 billion.

The slide meant AstraZeneca lost its position as the second-largest listed company in the UK to Shell. The stock’s decline made it one of the biggest laggards on the FTSE 100 (UKX) and contributed to broader index weakness. In contrast, reports said Bristol Myers’ (BMY) shares rose in U.S. trading as investors weighed the potential benefits of the tie-up for the smaller company.

Despite the scale of the market reaction, neither company confirmed that any transaction is under active consideration. AstraZeneca declined to comment on the reports of merger talks. Bristol Myers Squibb did not immediately respond to requests for comment during U.S. off-hours.

The absence of official statements has left open the possibility that discussions may not lead to a formal offer. Reports stressed that any deal remains hypothetical at this stage. Investors therefore must balance the immediate share-price moves against the uncertainty surrounding whether a transaction will proceed.

Analysts expressed scepticism about the strategic rationale for a merger of this size. Some pointed to AstraZeneca’s existing growth profile and pipeline strength as reasons to question the benefits of such a large and complex combination. There were also questions about how the companies’ oncology and broader product franchises would be integrated.

Commentary highlighted that a $400 billion-class pharmaceutical merger would likely face intense antitrust scrutiny. Any deal would be examined closely by competition regulators, particularly in major markets. These regulatory risks, together with integration challenges and the early-stage nature of the talks, were cited as key uncertainties surrounding the potential tie-up.